Clinical Trial Update: Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 [Phase 3]

View source ↗

Summary

Phase 3 trial update on reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2015-12-22